Cargando…

In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer

BACKGROUND: We examined the anti-tumor effect and radiosensitizing potential of a small molecule inhibitor of fibroblast growth factor receptor (FGFR) in colorectal cancer (CRC) in vitro and in vivo. METHODS: Effects of in vitro drug treatment on cell survival, proliferation, FGFR signaling, cell cy...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstraete, Maud, Debucquoy, Annelies, Gonnissen, Annelies, Dok, Ruveyda, Isebaert, Sofie, Devos, Ellen, McBride, William, Haustermans, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682227/
https://www.ncbi.nlm.nih.gov/pubmed/26675289
http://dx.doi.org/10.1186/s12885-015-2000-8
_version_ 1782405861011881984
author Verstraete, Maud
Debucquoy, Annelies
Gonnissen, Annelies
Dok, Ruveyda
Isebaert, Sofie
Devos, Ellen
McBride, William
Haustermans, Karin
author_facet Verstraete, Maud
Debucquoy, Annelies
Gonnissen, Annelies
Dok, Ruveyda
Isebaert, Sofie
Devos, Ellen
McBride, William
Haustermans, Karin
author_sort Verstraete, Maud
collection PubMed
description BACKGROUND: We examined the anti-tumor effect and radiosensitizing potential of a small molecule inhibitor of fibroblast growth factor receptor (FGFR) in colorectal cancer (CRC) in vitro and in vivo. METHODS: Effects of in vitro drug treatment on cell survival, proliferation, FGFR signaling, cell cycle distribution, apoptosis and radiosensitivity were assessed using various CRC cell lines with FGFR wild type (Caco2 and HCA7) and FGFR2 amplification (HCT116, NCI-H716). In vivo tumor responses to FGFR inhibition with and without radiation therapy were evaluated by growth delay assays in two colorectal xenograft mouse models (NMRI nu/nu mice injected with NCI-H716 or CaCo2 cells). Mechanistic studies were conducted using Western blot analysis, immunohistochemistry and qPCR. RESULTS: In the tested cell lines, the FGFR inhibitor (JNJ-42756493) was effective in vitro and in vivo in CRC tumors with highest expression of FGFR2 (NCI-H716). In vitro, cell proliferation in this line was decreased, associated with increased apoptotic death and decreased cell survival. In vivo, growth of NCI-H716 tumors was delayed by 5 days by drug treatment alone, although when drug delivery was stopped the relative tumor volume increased compared to control. The FGFR inhibitor did not radiosensitize NCI-H716 tumors either in vitro or in vivo. CONCLUSIONS: Among tested CRC cell lines, the growth inhibitory activity of this FGFR inhibitor was evident in cell lines with high constitutive FGFR2 expression, suggesting that FGFR addiction may provide a window for therapeutic intervention, though caution is advised. Preclinical study with NCI-H716 and Caco2 tumor demonstrated that continued presence of drug could be essential for tumor growth control, especially in cells with aberrant FGFR expression. In the tested set-up, the inhibitor showed no radiosensitizing effect. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-2000-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4682227
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46822272015-12-18 In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer Verstraete, Maud Debucquoy, Annelies Gonnissen, Annelies Dok, Ruveyda Isebaert, Sofie Devos, Ellen McBride, William Haustermans, Karin BMC Cancer Research Article BACKGROUND: We examined the anti-tumor effect and radiosensitizing potential of a small molecule inhibitor of fibroblast growth factor receptor (FGFR) in colorectal cancer (CRC) in vitro and in vivo. METHODS: Effects of in vitro drug treatment on cell survival, proliferation, FGFR signaling, cell cycle distribution, apoptosis and radiosensitivity were assessed using various CRC cell lines with FGFR wild type (Caco2 and HCA7) and FGFR2 amplification (HCT116, NCI-H716). In vivo tumor responses to FGFR inhibition with and without radiation therapy were evaluated by growth delay assays in two colorectal xenograft mouse models (NMRI nu/nu mice injected with NCI-H716 or CaCo2 cells). Mechanistic studies were conducted using Western blot analysis, immunohistochemistry and qPCR. RESULTS: In the tested cell lines, the FGFR inhibitor (JNJ-42756493) was effective in vitro and in vivo in CRC tumors with highest expression of FGFR2 (NCI-H716). In vitro, cell proliferation in this line was decreased, associated with increased apoptotic death and decreased cell survival. In vivo, growth of NCI-H716 tumors was delayed by 5 days by drug treatment alone, although when drug delivery was stopped the relative tumor volume increased compared to control. The FGFR inhibitor did not radiosensitize NCI-H716 tumors either in vitro or in vivo. CONCLUSIONS: Among tested CRC cell lines, the growth inhibitory activity of this FGFR inhibitor was evident in cell lines with high constitutive FGFR2 expression, suggesting that FGFR addiction may provide a window for therapeutic intervention, though caution is advised. Preclinical study with NCI-H716 and Caco2 tumor demonstrated that continued presence of drug could be essential for tumor growth control, especially in cells with aberrant FGFR expression. In the tested set-up, the inhibitor showed no radiosensitizing effect. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-2000-8) contains supplementary material, which is available to authorized users. BioMed Central 2015-12-16 /pmc/articles/PMC4682227/ /pubmed/26675289 http://dx.doi.org/10.1186/s12885-015-2000-8 Text en © Verstraete et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Verstraete, Maud
Debucquoy, Annelies
Gonnissen, Annelies
Dok, Ruveyda
Isebaert, Sofie
Devos, Ellen
McBride, William
Haustermans, Karin
In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer
title In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer
title_full In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer
title_fullStr In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer
title_full_unstemmed In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer
title_short In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer
title_sort in vitro and in vivo evaluation of the radiosensitizing effect of a selective fgfr inhibitor (jnj-42756493) for rectal cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682227/
https://www.ncbi.nlm.nih.gov/pubmed/26675289
http://dx.doi.org/10.1186/s12885-015-2000-8
work_keys_str_mv AT verstraetemaud invitroandinvivoevaluationoftheradiosensitizingeffectofaselectivefgfrinhibitorjnj42756493forrectalcancer
AT debucquoyannelies invitroandinvivoevaluationoftheradiosensitizingeffectofaselectivefgfrinhibitorjnj42756493forrectalcancer
AT gonnissenannelies invitroandinvivoevaluationoftheradiosensitizingeffectofaselectivefgfrinhibitorjnj42756493forrectalcancer
AT dokruveyda invitroandinvivoevaluationoftheradiosensitizingeffectofaselectivefgfrinhibitorjnj42756493forrectalcancer
AT isebaertsofie invitroandinvivoevaluationoftheradiosensitizingeffectofaselectivefgfrinhibitorjnj42756493forrectalcancer
AT devosellen invitroandinvivoevaluationoftheradiosensitizingeffectofaselectivefgfrinhibitorjnj42756493forrectalcancer
AT mcbridewilliam invitroandinvivoevaluationoftheradiosensitizingeffectofaselectivefgfrinhibitorjnj42756493forrectalcancer
AT haustermanskarin invitroandinvivoevaluationoftheradiosensitizingeffectofaselectivefgfrinhibitorjnj42756493forrectalcancer